FindTrial
Sign In

Assessment of eyesight related outcome and quality of life during course of treatment with ANTI-VEGF injection in diabetic patients.

Assessment of visual outcome and quality of life during the course of treatment with intravitreal anti-VEGF injection in patients with diabetic macular edema. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/070519
Enrollment
60
Registered
2024-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H30-H36- Disorders of choroid and retina Health Condition 2: H358- Other specified retinal disorders

Interventions

Intervention1: Nil: Nil

Sponsors

Ramanpreet Kaur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with center involving diabetic macular edema requiring anti-VEGF injections Patients who are already undergoing treatment with intravitreal anti-VEGF injections

Exclusion criteria

Exclusion criteria: Patients with media opacities due to dense cataract , vitreous hemorrhage etc in whom it is difficult to assess posterior segment Patients with recent stroke less than 3 months who cannot be injected anti-VEGF Patient with other chronic comorbidities example inability to walk , hearing loss or visual loss due to causes other than DME that may affect quality of life Patients undergoing other intravitreal injections like steroids Patients who are not able to have adequate hearing and sight cognition to be able to complete interview questions

Design outcomes

Primary

MeasureTime frame
1 Visual acuity (log Mar scale) in patients before undergoing intravitreal anti VEGF injections in diabetic macular edema 2. The quality of life (NEI VFQ25 )in patients undergoing intravitreal anti-VEGF injections in diabetic macular edema 3. Visual acuity (log Mar scale)in patients with diabetic macular edema after intra vitreal anti-VEGF injections at 4 weeks,8 weeks,12 weeks.Timepoint: Visual acuity and NEIVFQ-25 score - baseline, 4 weeks, 8 weeks, 12 weeks after anti-VEGF injection.—

Secondary

MeasureTime frame
Visual acuity (log Mar scale)in patients with diabetic macular edema after intra vitreal anti-VEGF injections at 4 weeks,8 weeks,12 weeks.Timepoint: Visual acuity (log Mar scale)in patients with diabetic macular edema after intra vitreal anti-VEGF injections at 4 weeks, 8 weeks,12 weeks—

Countries

India

Contacts

Public ContactDr Neha Sethi

Guru Gobind Singh medical college and hospital Faridkot

nrgupta6@yahoo.co.in9872652220

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026